Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cytokinetics Inc chart...

About the Company

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

CEO

Robert Blum

Exchange

NASDAQ

Website

http://cytokinetics.com/

$337M

Total Revenue

447

Employees

$7B

Market Capitalization

-11.81

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CYTK News

Cytokinetics patents new cardiac myosin inhibitors

4d ago, source: BioWorld

Cytokinetics Inc. has disclosed cardiac myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, ...

Cytokinetics drifts lower as CEO touts standalone strategy

on MSN ago, source:

Cytokinetics (CYTK) stock slips after CEO suggests potential for upside without relying solely on a takeover, highlighting ...

Buy Rating Affirmed for Cytokinetics Amid Strong Clinical Progress and Strategic Commercial Preparations

17d ago, source: Business Insider

Begin your TipRanks Premium journey today. Cytokinetics (CYTK) Company Description: Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle ...

30 Biggest Biotechnology Companies in the World

1d ago, source: InvestingChannel on MSN

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn ...

This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag

18d ago, source: MarketWatch on MSN

Hello! This week’s ETF Wrap digs into the jump in biotech funds, as well as an “unusual” trend in U.S. small-cap stocks ...

CYTK Apr 2024 58.000 put

4d ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor ...

Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)

4d ago, source: Business Insider

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report), Cytokinetics (CYTK – Research Report) and Coherus Biosciences (CHRS – Research ...

Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7mon ago, source:

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of ...

100 Stocks You Should Have Invested In 5 Years Ago

13d ago, source:

If you know even a little bit about finance and investing, then you probably know that the stock market offers the most ...

Q4 2023 CytomX Therapeutics Inc Earnings Call

6d ago, source:

The pandemic validated the disease-fighting prowess of mRNA vaccines. Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer ...

Ionis stock jumps as MASH drug succeeds in mid-stage trial

5d ago, source:

Ionis Pharmaceuticals reported positive results from a Phase 2 study of its investigational drug for fatty liver disease.

ALS body takes digital approach to clinical trials access

3d ago, source: pharmaphorum

A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...